Stephen Pettitt

28PUBLICATIONS
215CO-AUTHORS
Molecular targetsHealth and ecological risk assessmentPredictive and prognostic markersMedical molecular engineering of nucleic acids and proteinsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Jul 15, 2026
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

|Jul 10, 2026
The PRECISE European initiative for cancer-vulnerability mapping and prediction.

|Jul 29, 2025
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.

Roman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki

|Jul 08, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

Joan Kyula-Currie, Victoria Roulstone, James Wright

|Mar 03, 2025
The transcriptomic architecture of common cancers reflects synthetic lethal interactions.

Syed Haider, Rachel Brough, Santiago Madera

|Feb 12, 2025
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.

James Stewart, Dragomir B Krastev, Rachel Brough

Pageof 5

Frequent Collaborators

20 joint publications

Christopher J Lord

9 joint publications

Andrew Nj Tutt

7 joint publications

Syed Haider

7 joint publications

Dragomir Krastev